Dr Reddy's launches bevacizumab biosimilar Versavo in the UK

Biosimilars/News | Posted 27/03/2024 post-comment0 Post your comment

On 19 March 2024, Dr Reddy’s Laboratories announced that it would be launching Versavo, a bevacizumab biosimilar, in the UK.

22 AA010963

Versavo is a bevacizumab biosimilar of Roche’s originator, Avastin, granted marketing authorization from the UK in November 2023.

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers [1]. 

Versavo is indicated for the treatment of several types of cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer and metastatic breast cancer.

Being the first biosimilar from Dr Reddy's to secure approval and be launched in the UK, Versavo is available in strengths of 100 mg and 400 mg single-use vials in the country.  While Amgen's Mvasi became the first bevacizumab biosimilar to gain approval in the UK back in January 2018, Versavo, despite being available in the UK, has not been submitted for approval in the European Union.

The product was first approved and launched in India in 2019 [2], and subsequently introduced in other markets including Thailand, Ukraine, Nepal, and Jamaica under the same brand name. However, in Colombia, the product was launched under the brand name Persivia.

Global Head of Biologics at Dr Reddy’s Jayanth Sridhar said, ‘Launch of Versavo in a highly regulated market underscores our capability for global clinical development of high-quality biosimilar products’.

Related articles
FDA approves bevacizumab biosimilar Avzivi

Celltrion: advances for Yuflyma and Vegzelma biosimilars 

Clinical study advances for Alvotech golimumab and Dr Reddy’s rituximab biosimilars

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Cuestionando la necesidad de evaluaciones de sensibilidad étnica para anticuerpos monoclonales biosimilares

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Cuestionando la necesidad de evaluaciones de sensibilidad étnica para anticuerpos monoclonales biosimilares

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Mar 27]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-bevacizumab
2. GaBI Online - Generics and Biosimilars Initiative. Bevacizumab ‘similar biologic’ Versavo launched in India [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Mar 27]. Available from: www.gabionline.net/biosimilars/news/Bevacizumab-similar-biologic-Versavo-launched-in-India

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010